SNSE Stock Price, Sensei Biotherapeutics, . Quote, Chart

Market Summary

USD1.54-0.05

Delayedas of 17 May 2024, 03:01 pm

-3.14%

SNSE Stock Price

View Fullscreen

SNSE RSI Chart

SNSE Valuation

Market Cap

39.9M

Price/Earnings (Trailing)

-1.25

Price/Sales (Trailing)

11.65

Price/Free Cashflow

-1.43

SNSE Price/Sales (Trailing)

SNSE Profitability

Return on Equity

-54.6%

Return on Assets

-47.87%

Free Cashflow Yield

-70.14%

SNSE Fundamentals

SNSE Revenue

Revenue (TTM)

3.4M

Rev. Growth (Yr)

-20.74%

Rev. Growth (Qtr)

-7.02%

SNSE Earnings

Earnings (TTM)

-31.9M

Earnings Growth (Yr)

21.39%

Earnings Growth (Qtr)

-7.9%

Breaking Down SNSE Revenue

52 Week Range

0.681.66

(Low)(High)

Last 7 days

2.6%

Last 30 days

62.6%

Last 90 days

111.8%

Trailing 12 Months

7.3%

How does SNSE drawdown profile look like?

SNSE Financial Health

Current Ratio

12.07

SNSE Investor Care

Buy Backs (1Y)

19.04%

Diluted EPS (TTM)

-1.21

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	3.4M	0	0	0
2023	2.4M	3.0M	3.4M	3.6M
2022	1.0M	1.3M	1.5M	1.8M
2021	0	0	0	800.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Sensei Biotherapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 15, 2024	celebi john	sold (taxes)	-4,653	0.79	-5,891	president and ceo
Feb 15, 2024	colgan erin	sold (taxes)	-2,865	0.79	-3,627	chief financial officer
Feb 15, 2024	van der horst edward	sold (taxes)	-2,245	0.79	-2,843	chief scientific officer
Sep 11, 2023	celebi john	bought	425	0.85	500	president and ceo
Jul 31, 2023	peyer james	back to issuer	-2,000,000	1.26	-1,587,300	-
Jul 31, 2023	cambrian biopharma inc	back to issuer	-2,000,000	1.26	-1,587,300	-
Jul 10, 2023	cambrian biopharma inc	acquired	-	-	4,466	-
Jul 10, 2023	peyer james	acquired	-	-	4,466	-
Jul 10, 2023	holmen bob	acquired	-	-	4,466	-
Jul 10, 2023	ringo william r	acquired	-	-	4,466	-

Which funds bought or sold SNSE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	9,227	27,063	-%
May 15, 2024	MORGAN STANLEY	added	5,479	12,679	12,830	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-0.03	32,475	95,301	-%
May 15, 2024	Cresset Asset Management, LLC	new	-	20,655	20,655	-%
May 15, 2024	Newtyn Management, LLC	reduced	-40.83	-111,099	976,741	0.20%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-20.51	1,205	7,049	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	unchanged	-	6,802	19,950	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-14.91	7,716	34,216	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	unchanged	-	3,643	10,685	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	40,418	118,545	-%

Are Funds Buying or Selling SNSE?

Are funds buying SNSE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SNSE

No. of Funds

Unveiling Sensei Biotherapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 07, 2024	newtyn management, llc	2.21%	554,493	SC 13D/A
Feb 13, 2024	newtyn management, llc	3.%	768,921	SC 13D/A
Nov 03, 2023	newtyn management, llc	3.9%	1,046,406	SC 13D
Aug 04, 2023	cambrian biopharma inc	0.0%	0	SC 13G/A
Jun 02, 2023	apeiron investment group ltd.	-	0	SC 13D/A
May 23, 2023	apeiron investment group ltd.	3.1%	955,738	SC 13D/A
Mar 09, 2023	apeiron investment group ltd.	3.1%	955,738	SC 13D/A
Feb 14, 2023	cambrian biopharma inc	0.0%	0	SC 13G/A
Nov 21, 2022	apeiron investment group ltd.	3.1%	955,738	SC 13D/A
Nov 02, 2022	apeiron investment group ltd.	3.1%	955,738	SC 13D/A

Recent SEC filings of Sensei Biotherapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	3	Insider Trading
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 12, 2024	8-K	Current Report
Apr 02, 2024	8-K	Current Report
Mar 07, 2024	SC 13D/A	13D - Major Acquisition
Mar 05, 2024	8-K	Current Report

Peers (Alternatives to Sensei Biotherapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Sensei Biotherapeutics, Inc. News

Latest updates

Sensei Biotherapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)												(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Revenue	-7.0%	768	826	877	952	969	609	515	349	310	294	278	188
Operating Expenses	7.2%	8,730	8,142	7,737	10,177	11,008	13,048	13,941	10,712	12,487	9,413	10,316	9,784
S&GA Expenses	-100.0%	-	3,649	3,919	5,393	5,804	5,703	4,751	4,319	5,032	3,457	3,873	3,886
Interest Expenses	-9.7%	28.00	31.00	33.00	38.00	42.00	-206	10.00	172	243	306	214	147
Net Income	-7.9%	-8,000	-7,414	-7,124	-9,386	-10,177	-12,232	-13,416	-10,535	-12,405	-9,366	-9,685	-9,771
Net Income Margin	0.9%	-9.33*	-9.41*	-11.42*	-14.85*	-18.98*	-27.25*	-29.74*	-32.51*	-39.42*	-45.99*	-	-
Free Cashflow	-24.2%	-7,653	-6,163	-4,661	-9,492	-11,887	-9,574	-7,053	-11,951	-10,769	-8,403	-5,965	-6,663

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-10.3%	67.00	74.00	82.00	90.00	108	118	129	138	150	153	161	168	174	21.00
Current Assets	-10.4%	60.00	67.00	74.00	81.00	99.00	109	118	127	139	149	158	166	173	20.00
Cash Equivalents	-15.8%	11.00	13.00	11.00	10.00	8.00	18.00	11.00	10.00	9.00	7.00	10.00	16.00	169	17.00
Net PPE	-8.6%	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	5.00	3.00	2.00	2.00	1.00
Liabilities	-13.3%	8.00	9.00	11.00	10.00	13.00	15.00	15.00	12.00	15.00	7.00	6.00	5.00	3.00	6.00
Current Liabilities	-11.5%	5.00	6.00	6.00	5.00	8.00	9.00	8.00	5.00	8.00	5.00	5.00	4.00	2.00	5.00
Shareholder's Equity	-9.9%	58.00	65.00	71.00	79.00	95.00	103	114	126	135	147	155	163	171	-
Retained Earnings	-3.5%	-239	-231	-224	-217	-207	-197	-185	-172	-161	-149	-139	-130	-120	-112
Additional Paid-In Capital	0.5%	298	297	296	297	304	302	301	299	298	296	295	293	292	56.00
Shares Outstanding	0.2%	25.00	25.00	25.00	27.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	25.00	-	-
Float	-	-	-	-	19.00	-	-	-	36.00	-	-	-	204	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-23.6%	-7,616	-6,163	-4,661	-9,463	-11,736	-9,574	-6,803	-11,899	-10,750	-7,868	-5,577	-6,047	-10,767	-2,680	-5,798	-2,767	-6,460
Share Based Compensation	10.7%	1,216	1,098	1,048	1,095	1,213	1,399	1,479	1,419	1,515	826	1,736	1,746	1,349	354	781	163	194
Cashflow From Investing	-30.2%	5,770	8,262	8,312	19,526	2,312	16,043	8,517	13,196	12,193	5,612	-482	-147,761	-487	-316	-836	-199	-52.00
Cashflow From Financing	51.5%	-209	-431	-2,534	-7,946	-262	-124	-	-	119	-118	-7.00	-11.00	164,076	15,859	8,481	556	10,557

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SNSE Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 4,917	$ 5,204
General and administrative	3,813	5,804
Total operating expenses	8,730	11,008
Loss from operations	(8,730)	(11,008)
Other income (expense):
Interest income	768	969
Interest expense	(28)	(42)
Loss on asset disposal		(105)
Other (expense) income, net	(2)	9
Net loss	$ (7,992)	$ (10,177)
Net loss per common share, basic	$ (0.32)	$ (0.33)
Net loss per common share, diluted	$ (0.32)	$ (0.33)
Weighted-average number of shares used in computing net loss per common share, basic	25,049,111	30,866,087
Weighted-average number of shares used in computing net loss per common share, diluted	25,049,111	30,866,087
Comprehensive loss:
Net loss	$ (7,992)	$ (10,177)
Other comprehensive items:
Unrealized gain on marketable securities	72	181
Total other comprehensive income	72	181
Total comprehensive loss	$ (7,920)	$ (9,996)

SNSE Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 10,956	$ 13,011
Marketable securities	47,125	52,746
Prepaid expenses	1,884	1,168
Other current assets	269	325
Total current assets	60,234	67,250
Right of use assets - operating leases, net	3,960	4,330
Right of use assets - financing leases, net	1,350	1,543
Property and equipment, net	1,065	1,165
Other non-current assets	86	86
Total assets	66,695	74,374
Current liabilities:
Accounts payable and accrued liabilities	2,000	1,694
Compensation and employee benefits liabilities	514	1,510
Operating lease liabilities, current	1,607	1,567
Financing lease liabilities, current	871	872
Total current liabilities	4,992	5,643
Operating lease liabilities, non-current	2,590	3,001
Financing lease liabilities, non-current	571	768
Other non-current liabilities	68	67
Total liabilities	8,221	9,479
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, $0.0001 par value and 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; zero shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively
Common stock, $0.0001 par value and 250,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 25,073,958 and 25,030,188 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	3	3
Additional paid-in capital	298,495	296,996
Accumulated deficit	(239,887)	(231,895)
Accumulated other comprehensive loss	(137)	(209)
Total stockholders' equity	58,474	64,895
Total liabilities and stockholders' equity	$ 66,695	$ 74,374

About Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company's pipeline includes SNS-101, SNS-103, and SNS-102, monoclonal antibodies, which are in early development stages for the treatment of solid tumors. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

CEO	Mr. John K. Celebi M.B.A., MBA
WEBSITE	senseibio.com
INDUSTRY	Biotechnology
EMPLOYEES	23

Sensei Biotherapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Sensei Biotherapeutics, Inc.? What does SNSE stand for in stocks?

SNSE is the stock ticker symbol of Sensei Biotherapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sensei Biotherapeutics, Inc. (SNSE)?

As of Thu May 16 2024, market cap of Sensei Biotherapeutics, Inc. is 39.88 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNSE stock?

You can check SNSE's fair value in chart for subscribers.

What is the fair value of SNSE stock?

You can check SNSE's fair value in chart for subscribers. The fair value of Sensei Biotherapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sensei Biotherapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SNSE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sensei Biotherapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether SNSE is over valued or under valued. Whether Sensei Biotherapeutics, Inc. is cheap or expensive depends on the assumptions which impact Sensei Biotherapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNSE.

What is Sensei Biotherapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, SNSE's PE ratio (Price to Earnings) is -1.25 and Price to Sales (PS) ratio is 11.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNSE PE ratio will change depending on the future growth rate expectations of investors.